EvaluatePharma Alpha

Helping you to find value in pharma and biotech 

Overview of Alpha service: 

EvaluatePharma Alpha is a cutting-edge analysis and intelligence service for the pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

• Global coverage of over 3000 consensus based product NPVs linked to share price and company valuation
• Comprehensive pharmaceutical market analysis with over 90% coverage of all listed companies above $300m market capital 
• Interactive NPV Analyzer with full transparency and multiple inputs for each product
• Real time analysis with email alerts and share prices updated daily in line with NPV movements 
• Calendar of Events an unrivalled tracking tool on key events set to impact product and company valuations 
• Daily editorial comment and analysis from EP Vantage with key opinion leader insight and proprietary quantitative analysis 

Plus content from EvaluatePharma:

• Product consensus forecasts to 2012, compiled from reports published by leading equity analysts
• In-depth company financial data, including P&L, Balance Sheet, Cash Flow, Shareholder Returns, and Financial Ratios, with five-year forecasts
• Historic sales data drawn from the most complete and reliable sources of industry data – the reporting companies themselves
• Dynamic market sizing and benchmarking
• Peer Group Analyzer and forecast trends

Coverage and depth of data:

EvaluatePharma offers clients comprehensive worldwide coverage of the pharma and biotech sectors with a quality of data that is unmatched. The depth and integrity of our data is paramount and is a key distinguishing feature of our service. All EvaluatePharma data is collated and validated by our team of analysts to ensure accuracy and integrity and is consistently verified to maintain the highest quality standards. Our consensus forecasts are based upon the most influential forecasts in the investment banking sector.

With coverage of over 900 pharma and biotech companies, 13,500 products and 3,000 product consensus NPVs, EvaluatePharma Alpha provides you with the specialist industry knowledge and level of detail needed to support your investment decisions including:

• Ranking companies by market capital, market share, sales, pipeline products, therapeutic areas plus many more criteria
• Dynamic market sizing by therapeutic areas, ATC code or pharmacological class
• Benchmarking pipeline products by therapy area, development phases and product sourcing strategy